Lung cancer study seeks optimal immunotherapy duration
NCT ID NCT04880382
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looked at how long immunotherapy (a treatment that helps the immune system fight cancer) should be given to people with non-small cell lung cancer who had already responded well to it. The goal was to see if stopping treatment earlier or continuing longer was better. Only 8 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de la Côte Basque
Bayonne, 64109, France
-
Clinique Marzet
Pau, France
-
Clinique Tivoli Ducos
Bordeaux, 33000, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, 33077, France
Conditions
Explore the condition pages connected to this study.